AU2001261519A1 - Methods of affecting laminin 5 processing - Google Patents

Methods of affecting laminin 5 processing

Info

Publication number
AU2001261519A1
AU2001261519A1 AU2001261519A AU6151901A AU2001261519A1 AU 2001261519 A1 AU2001261519 A1 AU 2001261519A1 AU 2001261519 A AU2001261519 A AU 2001261519A AU 6151901 A AU6151901 A AU 6151901A AU 2001261519 A1 AU2001261519 A1 AU 2001261519A1
Authority
AU
Australia
Prior art keywords
methods
processing
laminin
affecting
affecting laminin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261519A
Inventor
Paul R. Findell
M. Peter Marinkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Leland Stanford Junior University
Original Assignee
Fibrogen Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc, Leland Stanford Junior University filed Critical Fibrogen Inc
Publication of AU2001261519A1 publication Critical patent/AU2001261519A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AU2001261519A 2000-05-12 2001-05-11 Methods of affecting laminin 5 processing Abandoned AU2001261519A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20370800P 2000-05-12 2000-05-12
US60/203,708 2000-05-12
PCT/US2001/015417 WO2001087239A2 (en) 2000-05-12 2001-05-11 Methods of affecting laminin 5 processing

Publications (1)

Publication Number Publication Date
AU2001261519A1 true AU2001261519A1 (en) 2001-11-26

Family

ID=22754988

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261519A Abandoned AU2001261519A1 (en) 2000-05-12 2001-05-11 Methods of affecting laminin 5 processing

Country Status (4)

Country Link
US (1) US20020076736A1 (en)
EP (1) EP1280553A2 (en)
AU (1) AU2001261519A1 (en)
WO (1) WO2001087239A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955924B2 (en) 1994-10-04 2005-10-18 Biostratum, Inc. Laminin chains: diagnostic uses
US20020155440A1 (en) * 2000-12-19 2002-10-24 Ljubimova Julia Y. Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors
US8911717B2 (en) 2003-12-05 2014-12-16 Cedars-Sinai Medical Center Polymalic acid-based multifunctional drug delivery system
ES2717836T3 (en) 2003-12-05 2019-06-25 Arrogene Inc Multifunctional drug delivery system based on polymic acid
US7323551B2 (en) * 2004-01-27 2008-01-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inhibiting squamous cell carcinoma
US7875277B2 (en) * 2004-01-27 2011-01-25 The Dept. of Veterans Affairs Office of The General Counsel Compositions and methods for inhibiting squamous cell carcinoma
US20100260764A1 (en) * 2007-08-29 2010-10-14 Marinkovich M Peter Compositions and methods for inhibiting squamous cell carcinoma
WO2011072240A1 (en) 2009-12-10 2011-06-16 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
US9623041B2 (en) 2010-12-30 2017-04-18 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions
US20140045196A1 (en) * 2012-08-13 2014-02-13 University Of Tokyo Methods of prognosis and diagnosis of cancer
JPWO2022124266A1 (en) * 2020-12-07 2022-06-16

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211657A (en) * 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
AU1329700A (en) * 1998-10-30 2000-05-22 Northwestern University Method of interfering with cell proliferation
US6506936B1 (en) * 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
US6462063B1 (en) * 2000-02-04 2002-10-08 Fibrogen, Inc. C-proteinase inhibitors

Also Published As

Publication number Publication date
EP1280553A2 (en) 2003-02-05
WO2001087239A3 (en) 2002-08-29
US20020076736A1 (en) 2002-06-20
WO2001087239A2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
EP1241577A3 (en) Methods and arrangements for improved parity-stripe processing
AU4496800A (en) Laminin 2 and methods for its use
AU2002239740A1 (en) Nanolithography methods and products therefor and produced thereby
AU2001294549A1 (en) Process and intermediates
AU1488501A (en) Methods of inhibiting metastasis
AU2001261519A1 (en) Methods of affecting laminin 5 processing
AU2001267428A1 (en) Direct detection of individual molecules
AU2001229770A1 (en) Improved research and development process
AU2002231206A1 (en) Treatment of depression
AU2002219900A1 (en) Minimal identification of features
AU4678400A (en) Laminin 8 and methods for its use
AU2001247196A1 (en) Methods and compositions for detection of disease
AU2001229530A1 (en) Detection of fermentation-related microorganisms
AUPQ885500A0 (en) Enhancement of products
GB0020717D0 (en) Novel compounds and process
AU2001262963A1 (en) Laminin 15 and uses thereof
AU2001295579A1 (en) Pants and method for the production thereof
AU2001278951A1 (en) Compounds and methods
AU2001251004A1 (en) Detection of viable agents
AU2207001A (en) Novel compounds and process
AU2002242348A1 (en) Process for obtaining 3'-epilutein
AU2001286489A1 (en) Process for the purification of iosoctane and/or diisobutylene
AU2001283030A1 (en) Process for making 3-hydroxyalkanenitriles and hydroxyaminoalkanes
AU2001274004A1 (en) Method for the production of 2- coumarone and substituted 2-coumarones
AU2001220267A1 (en) Novel 1beta-methylcarbapenem derivatives and process of preparation thereof